Detection of the Platelet Activation Markers CD62p and PAC-1 in Patients with Hypertension and Coronary Heart Disease
10.3969/j.issn.1671-7414.2014.06.035
- VernacularTitle:高血压、冠心病患者血小板微粒活化标记物CD62 p和PAC-1检测的临床意义
- Author:
Xiaodan ZHANG
;
Chengyan ZHAO
;
Xiaolin HE
;
Rong MA
;
Min WANG
- Publication Type:Journal Article
- Keywords:
CD62p;
PAC-1;
hypertension;
coronary heart disease
- From:
Journal of Modern Laboratory Medicine
2014;(6):110-112
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical significance of platelet activation markers CD62p and PAC-1 in patients with hypertension and coronary heart diease.Methods To select patients who were in the Second Affiliated Hospital of Dalian Medical University between January 2012 and September 2012,42 patients with hypertension,46 patients with coronary heart disease.Flow cytometry was used to test the positive percentage of the platelet surface activation markers CD62p and PAC-1 .To observe the difference among hypertension group,coronary heart disease group and health control group;hyper-tension and coronary heart disease group.Results The positive percentage of platelet activation markers CD62p and PAC-1 in hypertension (36.36±9.62,7.18±8.20)%,coronary heart disease group (42.74±14.60,8.81±12.53)% showed sta-tistically significant differences (t=4.150~5.853,P<0.01)compared with healthy control group (26.82±9.13 ,1.09± 1.05)%.The positive percentage of CD62p in coronary heart disease group (42.74±14.60)% was also higher than that of hypertension (36.36±9.62)%,and the difference between them was of statistical significance (t=2.444,P<0.05).Con-clusion The hypertensive patients and coronary heart disease were in pre-thrombotic state,the activation of platelet increase significantly.Molecular markers should be measured in hypertensive patients and coronary heart disease for prevention and treatment of thrombotic disease complication.
